Evidence-Based Recommendations for the Use of Desidustat in Chronic Kidney Disease

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Background:

• Anemia is a significant complication of chronic kidney disease (CKD), impacting patient quality of life and increasing mortality.
• Current treatments like erythropoiesis-stimulating agents (ESAs) have limitations, including hyporesponsiveness and safety concerns.
• Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) represent a new therapeutic approach for anemia in CKD.

Purpose of the Study:

• To review the evidence for desidustat, a HIF-PHI, in managing anemia across different stages of CKD.
• To provide practical, evidence-based recommendations for desidustat use.
• To inform clinical practice based on recent KDIGO guidelines.

Main Methods:

• Systematic review of existing clinical trial data and observational studies on desidustat.
• Analysis of desidustat's efficacy and safety profiles in CKD patients.
• Synthesis of findings in the context of current anemia management guidelines.

Main Results:

• HIF-PHIs, including desidustat, stimulate endogenous erythropoietin production.
• These agents also improve iron metabolism, addressing a key challenge in CKD anemia.
• Desidustat shows promise as an effective alternative to traditional therapies.

Conclusions:

• Desidustat is a viable therapeutic option for CKD-associated anemia, as supported by emerging evidence.
• The KDIGO guidelines now recognize HIF-PHIs as alternatives for selected CKD patients.
• Further research and clinical experience will refine desidustat's role in CKD management.